David Deere, PaizaBio01.28.16
China’s Food and Drug Administration (cFDA) has recently published long anticipated reforms designed to accelerate the regulatory review of new drugs and expand options for manufacturing those approved. The new policies, which went into effect December 1, are posted on cFDA’s website, and will impact both Chinese and Western pharmaceutical companies.
The reforms represent major changes in China’s drug development and commercialization policies, addressing critical areas: accelerating the high-volume backlog of drugs awaiting review and approval by the cFDA and fostering domestic clinical drug development and manufacturing to international technical and quality standards.
Streamlining Drug Review
Streamlining the review of innovative new drugs is a top priority of the cFDA given growing public health issues that stand to benefit from effective pharmaceutical treatments. The new regulatory policy significantly expands the types of drugs that may qualify for a streamlined review process via the Fast Track or green approval pathway and redefines what qualifies as a new drug. Prior to the policy change, the Fast Track regulatory approval pathway was limited to novel drugs not approved for use anywhere in the world or drugs addressing areas of critical and high unmet medical need.
The following drug categories stand to benefit from China’s redefined Fast Track regulatory approval pathway:
Redefining “new”
The new policies also seek to clarify what constitutes a “new” drug. The cFDA now defines new drugs as only those pharmaceutical products that have never been marketed anywhere in the world or those that represent an improved form of the new drug. Generic drugs are defined as pharmaceutical products that are consistent with the reference or originator drug in terms of quality or efficacy. The cFDA plans to introduce a classification system to address these new definition categories.
To facilitate clinical development of new drugs in China, the cFDA clinical trial application process will be streamlined; a single umbrella approval will replace the current system requiring approval at each phase of a trial.
Expanding Manufacturing Options
Historically, only China-based drug manufacturers could apply for approval to market new drugs in China. Drug research organizations without large scale manufacturing capabilities were required to transfer new drug innovations to a manufacturer that would then become the Marketing Authorization Holder (MAH).
This mandatory transferal of marketing rights created a disincentive for innovation and commercialization by research-based organizations at a time when China is focusing on building a more innovation-driven economy. The new policy now enables research-based organizations to commercialize their innovations while retaining marketing rights. As part of this development, China is launching a pilot MAH program in ten Chinese provinces allowing research-based organizations and individuals to outsource drug manufacturing to a contract manufacturing organization (CMO), while retaining marketing authorization status on approved drugs.
Impact on Multinational Pharma
China’s policy changes have the potential to significantly impact the global clinical development and manufacturing strategies of multinational pharmaceutical companies operating in China, according to Stuart Rose, founder and chief executive officer of PaizaBio, a company focused on helping western-based pharmaceutical companies manufacture drugs in China for the Chinese market. Mr. Rose was recently in China as a featured speaker at the 2015 China National Science and Technology Cooperation Week in Dongguan City, as a guest of Tsinghua University’s Donguan Innovation Center.
“With 1.4 billion people, China represents the largest drug market in the world. Yet western pharmaceutical companies have only a small foothold,” Mr. Rose said. “This is largely because China is a complicated environment for western companies in which to operate. These new policies reflect China’s growing willingness to engage multinationals in their drug development initiatives and allow contract manufacturing of new drugs in China for the Chinese market.”
Mr. Rose added, “Entering China is not easy; the new policies reflect China’s intent to be an active participant in global drug development and commercialization. That will make manufacturing in China for the Chinese market through a CMO like PaizaBio an attractive way to comply with cFDA policies and gain immediate access to China’s 1.4 billion citizens.”
Sources:
cFDA Announcement on 11/5/2015 of the Pilot Program for MAH http://www.sfda.gov.cn/WS01/CL0051/133921.html
cFDA Announcement on 11/13/ 2015 of Plans on Dealing with Backlog of Regulatory Filings http://www.sfda.gov.cn/WS01/CL0050/134823.html
David Deere is a veteran global pharmaceutical professional with product, line, and operational management roles with major multinational, specialty multinational, and small organizations based in the United States and abroad. Prior to joining PaizaBio, David served as vice president, Worldwide Marketing and Regulatory Affairs for Valeant Pharmaceuticals International. While at Valeant, he helped triple the company’s turnover and capitalization value and expanded its geographic presence through acquisitions with operations in 14 countries and a direct sales force in 30. He also served as global therapeutic head, ID/Virology, F. Hoffman-La Roche, AG, in Basel, Switzerland, and product director, Anti-Infectives, Genentech (formerly Roche Labs).
The reforms represent major changes in China’s drug development and commercialization policies, addressing critical areas: accelerating the high-volume backlog of drugs awaiting review and approval by the cFDA and fostering domestic clinical drug development and manufacturing to international technical and quality standards.
Streamlining Drug Review
Streamlining the review of innovative new drugs is a top priority of the cFDA given growing public health issues that stand to benefit from effective pharmaceutical treatments. The new regulatory policy significantly expands the types of drugs that may qualify for a streamlined review process via the Fast Track or green approval pathway and redefines what qualifies as a new drug. Prior to the policy change, the Fast Track regulatory approval pathway was limited to novel drugs not approved for use anywhere in the world or drugs addressing areas of critical and high unmet medical need.
The following drug categories stand to benefit from China’s redefined Fast Track regulatory approval pathway:
- Pediatric/geriatric drugs;
- Drugs sponsored by national science and technology related grants;
- Drugs to treat diseases or conditions prevalent in China;
- Foreign innovative drugs manufactured locally in China;
- Foreign drugs manufactured at a U.S.-FDA or EU-EMA qualified plant under review by the respective regulatory authorities (FDA/EMEA) for concurrent marketing authorizations; and
- Innovative drugs using advanced technology, using innovative treatment protocols or having significant clinical benefit.
Redefining “new”
The new policies also seek to clarify what constitutes a “new” drug. The cFDA now defines new drugs as only those pharmaceutical products that have never been marketed anywhere in the world or those that represent an improved form of the new drug. Generic drugs are defined as pharmaceutical products that are consistent with the reference or originator drug in terms of quality or efficacy. The cFDA plans to introduce a classification system to address these new definition categories.
To facilitate clinical development of new drugs in China, the cFDA clinical trial application process will be streamlined; a single umbrella approval will replace the current system requiring approval at each phase of a trial.
Expanding Manufacturing Options
Historically, only China-based drug manufacturers could apply for approval to market new drugs in China. Drug research organizations without large scale manufacturing capabilities were required to transfer new drug innovations to a manufacturer that would then become the Marketing Authorization Holder (MAH).
This mandatory transferal of marketing rights created a disincentive for innovation and commercialization by research-based organizations at a time when China is focusing on building a more innovation-driven economy. The new policy now enables research-based organizations to commercialize their innovations while retaining marketing rights. As part of this development, China is launching a pilot MAH program in ten Chinese provinces allowing research-based organizations and individuals to outsource drug manufacturing to a contract manufacturing organization (CMO), while retaining marketing authorization status on approved drugs.
Impact on Multinational Pharma
China’s policy changes have the potential to significantly impact the global clinical development and manufacturing strategies of multinational pharmaceutical companies operating in China, according to Stuart Rose, founder and chief executive officer of PaizaBio, a company focused on helping western-based pharmaceutical companies manufacture drugs in China for the Chinese market. Mr. Rose was recently in China as a featured speaker at the 2015 China National Science and Technology Cooperation Week in Dongguan City, as a guest of Tsinghua University’s Donguan Innovation Center.
“With 1.4 billion people, China represents the largest drug market in the world. Yet western pharmaceutical companies have only a small foothold,” Mr. Rose said. “This is largely because China is a complicated environment for western companies in which to operate. These new policies reflect China’s growing willingness to engage multinationals in their drug development initiatives and allow contract manufacturing of new drugs in China for the Chinese market.”
Mr. Rose added, “Entering China is not easy; the new policies reflect China’s intent to be an active participant in global drug development and commercialization. That will make manufacturing in China for the Chinese market through a CMO like PaizaBio an attractive way to comply with cFDA policies and gain immediate access to China’s 1.4 billion citizens.”
Sources:
cFDA Announcement on 11/5/2015 of the Pilot Program for MAH http://www.sfda.gov.cn/WS01/CL0051/133921.html
cFDA Announcement on 11/13/ 2015 of Plans on Dealing with Backlog of Regulatory Filings http://www.sfda.gov.cn/WS01/CL0050/134823.html
David Deere is a veteran global pharmaceutical professional with product, line, and operational management roles with major multinational, specialty multinational, and small organizations based in the United States and abroad. Prior to joining PaizaBio, David served as vice president, Worldwide Marketing and Regulatory Affairs for Valeant Pharmaceuticals International. While at Valeant, he helped triple the company’s turnover and capitalization value and expanded its geographic presence through acquisitions with operations in 14 countries and a direct sales force in 30. He also served as global therapeutic head, ID/Virology, F. Hoffman-La Roche, AG, in Basel, Switzerland, and product director, Anti-Infectives, Genentech (formerly Roche Labs).
